These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 25063251)

  • 1. Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete.
    Zhou J; Li J; Yan P; Ye YH; Peng W; Wang S; Wang XT
    Placenta; 2014 Sep; 35(9):691-5. PubMed ID: 25063251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased level of cell-free placental mRNA in a subgroup of placenta previa that needs hysterectomy.
    Miura K; Miura S; Yamasaki K; Yoshida A; Yoshiura K; Nakayama D; Niikawa N; Masuzaki H
    Prenat Diagn; 2008 Sep; 28(9):805-9. PubMed ID: 18646248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human placental lactogen mRNA in maternal plasma play a role in prenatal diagnosis of abnormally invasive placenta: yes or no?
    Li J; Zhang N; Zhang Y; Hu X; Gao G; Ye Y; Peng W; Zhou J
    Gynecol Endocrinol; 2019 Jul; 35(7):631-634. PubMed ID: 30784325
    [No Abstract]   [Full Text] [Related]  

  • 4. Second Trimester Biochemical Markers as Possible Predictors of Pathological Placentation: A Retrospective Case-Control Study.
    Berezowsky A; Pardo J; Ben-Zion M; Wiznitzer A; Aviram A
    Fetal Diagn Ther; 2019; 46(3):187-192. PubMed ID: 30726846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-free placental mRNA in maternal plasma to predict placental invasion in patients with placenta accreta.
    El Behery MM; Rasha L E; El Alfy Y
    Int J Gynaecol Obstet; 2010 Apr; 109(1):30-3. PubMed ID: 20070963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fraction of cell-free fetal DNA in the maternal serum as a predictor of abnormal placental invasion-a pilot study.
    Samuel A; Bonanno C; Oliphant A; Batey A; Wright JD
    Prenat Diagn; 2013 Nov; 33(11):1050-3. PubMed ID: 23836321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis.
    Jauniaux E; Bhide A
    Am J Obstet Gynecol; 2017 Jul; 217(1):27-36. PubMed ID: 28268196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal serum markers, characteristics and morbidly adherent placenta in women with previa.
    Lyell DJ; Faucett AM; Baer RJ; Blumenfeld YJ; Druzin ML; El-Sayed YY; Shaw GM; Currier RJ; Jelliffe-Pawlowski LL
    J Perinatol; 2015 Aug; 35(8):570-4. PubMed ID: 25927270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased placental and maternal serum TRAIL-R2 levels are associated with placenta accreta.
    Oztas E; Ozler S; Ersoy AO; Ersoy E; Caglar AT; Uygur D; Yucel A; Ergin M; Danisman N
    Placenta; 2016 Mar; 39():1-6. PubMed ID: 26992667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased levels of cell-free human placental lactogen mRNA at 28-32 gestational weeks in plasma of pregnant women with placenta previa and invasive placenta.
    Kawashima A; Sekizawa A; Ventura W; Koide K; Hori K; Okai T; Masashi Y; Furuya K; Mizumoto Y
    Reprod Sci; 2014 Feb; 21(2):215-20. PubMed ID: 23744883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prenatal identification of invasive placentation using ultrasound in women with placenta previa and prior cesarean delivery.
    Califano G; Saccone G; Maria Maruotti G; Bartolini G; Quaresima P; Morelli M; Venturella R; Votino C; Morlando M; Sarno L; Miceli M; Mazzulla R; Collà Ruvolo C; Nazzaro G; Locci M; Guida M; Berghella V; Bifulco G
    Eur J Obstet Gynecol Reprod Biol; 2024 Nov; 302():97-103. PubMed ID: 39241289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein.
    Zelop C; Nadel A; Frigoletto FD; Pauker S; MacMillan M; Benacerraf BR
    Obstet Gynecol; 1992 Oct; 80(4):693-4. PubMed ID: 1383899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta.
    Büke B; Akkaya H; Demir S; Sağol S; Şimşek D; Başol G; Barutçuoğlu B
    J Matern Fetal Neonatal Med; 2018 Jan; 31(1):59-62. PubMed ID: 28027672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First trimester maternal serum biochemical markers of aneuploidy in pregnancies with abnormally invasive placentation.
    Thompson O; Otigbah C; Nnochiri A; Sumithran E; Spencer K
    BJOG; 2015 Sep; 122(10):1370-6. PubMed ID: 25639820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Levels of Cell-Free miR-517a and Decreased Levels of Cell-Free miR-518b in Maternal Plasma Samples From Placenta Previa Pregnancies at 32 Weeks of Gestation.
    Hasegawa Y; Miura K; Higashijima A; Abe S; Miura S; Yoshiura K; Masuzaki H
    Reprod Sci; 2015 Dec; 22(12):1569-76. PubMed ID: 26040940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placenta previa, placenta accreta, and vasa previa.
    Oyelese Y; Smulian JC
    Obstet Gynecol; 2006 Apr; 107(4):927-41. PubMed ID: 16582134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers of abnormally invasive placenta.
    Al-Khan A; Youssef YH; Feldman KM; Illsley NP; Remache Y; Alvarez-Perez J; Mannion C; Alvarez M; Zamudio S
    Placenta; 2020 Feb; 91():37-42. PubMed ID: 32174305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasound accuracy in prenatal diagnosis of abnormal placentation of posterior placenta previa.
    Garofalo A; Pilloni E; Alemanno MG; Garofalo G; Sciarrone A; Todros T; Viora E
    Eur J Obstet Gynecol Reprod Biol; 2019 Nov; 242():86-91. PubMed ID: 31574389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of the routine first-trimester antenatal screening program for aneuploidy in the assessment of the risk of placenta accreta spectrum disorders.
    Penzhoyan GA; Makukhina TB
    J Perinat Med; 2019 Dec; 48(1):21-26. PubMed ID: 31730533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of targeted scanning protocols on perinatal outcomes in pregnancies at risk of placenta accreta spectrum or vasa previa.
    Melcer Y; Jauniaux E; Maymon S; Tsviban A; Pekar-Zlotin M; Betser M; Maymon R
    Am J Obstet Gynecol; 2018 Apr; 218(4):443.e1-443.e8. PubMed ID: 29353034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.